Celestia Diagnostics

Celestia Diagnostics, also known as Celestia Life Sciences, is a biotechnology company founded in 2022 that focuses on developing diagnostic medical tests and clinical bioinformatics platforms for complex, infection-associated chronic conditions. Their primary objective is to address the diagnostic void surrounding illnesses such as Long COVID, ME/CFS, and POTS. By building an integrated platform that includes a clinical laboratory, a biorepository of characterized cohorts, and clinical bioinformatics, the company aims to translate biomarkers into clinically practical tests, thereby reducing the time and cost of diagnostic development and enabling more personalized treatment pathways.

These efforts are intended to move complex post-infection conditions away from diagnosis by exclusion and toward objective, actionable clinical measures. By providing clinicians with reliable tools to support diagnosis and patient care, Celestia Diagnostics seeks to improve patient outcomes, streamline clinical trials, and create necessary development pathways for new therapies. The company operates out of Birmingham, Alabama, and has received support from initiatives such as Southern Research’s Therapeutic Development Fund to advance its mission of turning poorly understood syndromes into tractable, treatable diseases.